The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Clinical Trial on Palliative Cancer Patients With Constipation
Official Title: Chinese and Western Medicine Collaborative Studies on Palliative Cancer Patients With Constipation
Study ID: NCT02795390
Brief Summary: It is a double-blinded, randomized, placebo-controlled trial for advanced cancer patients with constipation. 60 patients will be randomly assigned to have individualized herbal intervention (treatment group) or placebo (control group) in 1:1 ratio. For the treatment group, MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules. Patients are instructed to dissolve the granules in 150ml of hot water, twice daily for two weeks. The primary end point is the global symptom improvement. Secondary outcome measures include stool frequency, stool form, use of rescue herbal granules, constipation visual analogue scale (CVAS) (0=none to 7=most severe) and individual assessment of constipation related symptoms. For the safety profiles of herbal intervention, the important adverse events reported and clinical laboratory evaluations of liver and renal function are determined.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Caritas Medical Centre, Hong Kong, , Hong Kong
Hong Kong Buddhist Hospital, Hong Kong, , Hong Kong
Our Lady of Maryknoll Hospital, Hong Kong, , Hong Kong
Name: Zhao-xiang Bian, PhD
Affiliation: Hong Kong Baptist University
Role: PRINCIPAL_INVESTIGATOR